Tapentadol is not just another opioid. The mu-opioid agonism is there, but it’s paired with noradrenaline reuptake inhibition in the same molecule. That second mechanism is what separates it from most of the alternatives pure opioids handle nociceptive pain, but neuropathic pain responds poorly to them. Noradrenaline modulation addresses the neuropathic component. So Tapentadol works on both at once, which is why it’s found consistent clinical use in diabetic peripheral neuropathy, lower back pain with a neuropathic element, and mixed-mechanism cancer pain.Tapentadol is not currently listed under the NDPS (Narcotic Drugs and Psychotropic Substances) Act in India.
Strava Healthcare manufactures Tapentadol tablets in India under Schedule H1 and applicable regulatory frameworks. Supply is restricted to licensed distributors, hospital supply chains, and export markets with valid licensing. All manufacture and distribution complies with proper rules and regulations.
Tapentadol tablets are widely used in pain management in African countries like Mali, Ghana and Niger.
Indications
Moderate to severe acute pain (post-surgical, traumatic, musculoskeletal), chronic pain with a neuropathic component, diabetic peripheral neuropathy, lower back pain, and cancer pain where mixed mechanisms are present.
IR vs ER: what matters practically?
Immediate-release tablets are for acute and as-needed dosing. Extended-release is for around-the-clock chronic pain management — not for as-needed use. ER tablets must be swallowed whole. Crushing or chewing destroys the release mechanism and dumps the full dose at once. That’s a serious safety issue and needs to be communicated clearly in prescribing and dispensing.
Manufacturing
GMP-certified, Schedule M compliant, NDPS Act provisions followed. Batch testing covers assay, dissolution, content uniformity, related substances, and microbiological purity. All batch documentation and COAs maintained per regulatory requirements. Supply only to entities with valid narcotic drug licences.
B2B and pharma partners
Contract manufacturing with custom strengths and compliant labelling. Private label for licensed distributors. Export supply to registered markets — dossier support and COPP available on request. Lead times and minimum quantities apply.
Product Specifications
| Parameter | Details |
|---|---|
| Active Ingredient | Tapentadol hydrochloride |
| IR strengths | 50 mg / 75 mg / 100 mg |
| ER strengths | 100 mg / 150 mg / 200 mg / 250 mg |
| Dosage form | Film-coated tablet (IR) / Extended-release tablet (ER) |
| Pack sizes | 10s blister; 100s bottle; per regulatory requirements |
| Storage | Below 30°C, protected from moisture |
| Shelf Life | 36 months |
Frequently Asked Questions
Both combine opioid and non-opioid mechanisms, but differently. Tramadol uses serotonin-noradrenaline reuptake inhibition alongside opioid agonism. Tapentadol uses only noradrenaline reuptake inhibition — no serotonergic activity. That matters clinically: no serotonin syndrome risk, fewer interaction concerns. GI side effects like nausea and vomiting are also generally better tolerated with Tapentadol at equivalent opioid doses.
With dose adjustment, yes. Elderly patients are more sensitive to CNS and respiratory opioid effects. Start low, titrate slowly. ER formulations should be introduced carefully. Renal impairment affects drug clearance and is common in older patients — check renal function before starting.
Available to countries where Tapentadol is registered and general import licensing is in place. Dossier support and COPP on request. Contact with destination market and volume requirements.